F D Roosevelt University General Hospital Of Banska Bystrica
- Address
- lock Available on a paid plan
F D Roosevelt University General Hospital Of Banska Bystrica - Comprehensive Clinical Research Center
F D Roosevelt University General Hospital of Banska Bystrica serves as a leading clinical research facility with extensive expertise across multiple therapeutic areas. The center demonstrates particular strength in inflammatory bowel diseases, nephrology, oncology, and neurological disorders, participating in numerous Phase 2 and Phase 3 international clinical trials.
- Inflammatory Bowel Disease Research: Comprehensive studies in ulcerative colitis and Crohn's disease, evaluating novel biologics, small molecules, and combination therapies including risankizumab, guselkumab, etrasimod, obefazimod, and mirikizumab
- Nephrology and Renal Disease: Advanced trials in chronic kidney disease, IgA nephropathy, focal segmental glomerulosclerosis, and minimal change disease, investigating emerging therapies for disease progression
- Oncology and Hematology: Multi-cancer research including colorectal cancer, biliary tract cancer, non-small cell lung cancer, multiple myeloma, chronic lymphocytic leukemia, neuroblastoma, and melanoma
- Neurological Disorders: Studies in relapsing multiple sclerosis with ofatumumab and remibrutinib, as well as stroke prevention research and refractory status epilepticus treatment
The hospital's research portfolio extends to specialized areas including dermatological conditions (vitiligo), cancer cachexia, pulmonary disease (COPD), age-related macular degeneration, and COVID-19 treatment in immunocompromised patients. The center's participation in long-term extension studies demonstrates commitment to evaluating sustained efficacy and safety profiles of investigational medications. With its multidisciplinary approach and infrastructure supporting complex trial designs including dose-finding studies, biosimilar comparisons, and adaptive platforms, the facility plays a crucial role in advancing therapeutic options for patients with serious and chronic medical conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 12 therapeutic areas and 15 of 136 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 135 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 21 by active trials.
- 1Janssen Cilag International3active
lock +20 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International7trials
lock +14 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in F D Roosevelt University General Hospital Of Banska Bystrica
lock Showing 1 of 65 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 136 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Guselkumab | 6 | Unknown | 2018-07-26 | 2026-05-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.